開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
Kremlin said it welcomed an invitation for Putin to attend the G20 summit in Miami and will study it.
2026-09-24
Kremlin said it welcomed an invitation for Putin to attend the G20 summit in Miami and will study it.
返回
其他消息
2026-09-24
Guojin Securities notes at the 2026 WCLC in Seoul Chinese innovative drugs featured prominently: Akeso’s Yiwoxi showed head-to-head superiority to pembrolizumab in first-line NSCLC; PD‑1/VEGF bispecifics are emerging as leaders in IO 2.0; B7‑H3 ADCs advanced to plenary sessions and ADC programs are pushing into frontline and perioperative use. Precision therapies targeting KRAS G12D, HER2 and EGFR resistance also posted clinical progress. The research note concludes Chinese bispecifics, ADCs and
Guojin Securities notes at the 2026 WCLC in Seoul Chinese innovative drugs featured prominently: Akeso’s Yiwoxi showed head-to-head superiority to pembrolizumab in first-line NSCLC; PD‑1/VEGF bispecifics are emerging as leaders in IO 2.0; B7‑H3 ADCs advanced to plenary sessions and ADC programs are pushing into frontline and perioperative use. Precision therapies targeting KRAS G12D, HER2 and EGFR resistance also posted clinical progress. The research note concludes Chinese bispecifics, ADCs and oligonucleotide candidates are globally competitive with leading data and could catalyze a new wave of outbound commercialization and sector valuation rerating.
2026-09-24
美國9月綜合PMI創2021年7月以來新高,通脹壓力再度加劇。黃金賣出信號顯示較強,原油多空情緒較爲平衡。歡迎前往“數據庫-嘉盛市場晴雨表”查看並訂閱(數據每10分鐘更新1次)
美國9月綜合PMI創2021年7月以來新高,通脹壓力再度加劇。黃金賣出信號顯示較強,原油多空情緒較爲平衡。歡迎前往“數據庫-嘉盛市場晴雨表”查看並訂閱(數據每10分鐘更新1次)
Chat with us
, powered by
LiveChat